Atara Biotherapeutics Statistics
Share Statistics
Atara Biotherapeutics has 5.76M shares outstanding. The number of shares has increased by -94.43% in one year.
| Shares Outstanding | 5.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 15.69% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.23M |
| Failed to Deliver (FTD) Shares | 240 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 636.28K, so 11.05% of the outstanding shares have been sold short.
| Short Interest | 636.28K |
| Short % of Shares Out | 11.05% |
| Short % of Float | 15.17% |
| Short Ratio (days to cover) | 7.11 |
Valuation Ratios
The PE ratio is -0.2 and the forward PE ratio is -1.33.
| PE Ratio | -0.2 |
| Forward PE | -1.33 |
| PS Ratio | 6.34 |
| Forward PS | 0.6 |
| PB Ratio | -0.55 |
| P/FCF Ratio | -0.28 |
| PEG Ratio | n/a |
Enterprise Valuation
Atara Biotherapeutics Inc. has an Enterprise Value (EV) of 86.20M.
| EV / Earnings | -0.31 |
| EV / Sales | 10.05 |
| EV / EBITDA | -0.32 |
| EV / EBIT | -0.31 |
| EV / FCF | -0.44 |
Financial Position
The company has a current ratio of 0.72, with a Debt / Equity ratio of 0.
| Current Ratio | 0.72 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -52.22 |
Financial Efficiency
Return on equity (ROE) is 2.78% and return on capital (ROIC) is 667.38%.
| Return on Equity (ROE) | 2.78% |
| Return on Assets (ROA) | -1.67% |
| Return on Capital (ROIC) | 667.38% |
| Revenue Per Employee | 51.96K |
| Profits Per Employee | -1.67M |
| Employee Count | 165 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.92 |
Taxes
| Income Tax | 15.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -30.93% in the last 52 weeks. The beta is 0.49, so Atara Biotherapeutics 's price volatility has been higher than the market average.
| Beta | 0.49 |
| 52-Week Price Change | -30.93% |
| 50-Day Moving Average | 10.45 |
| 200-Day Moving Average | 11.93 |
| Relative Strength Index (RSI) | 41.25 |
| Average Volume (20 Days) | 104.51K |
Income Statement
In the last 12 months, Atara Biotherapeutics had revenue of $8.57M and earned -$276.13M in profits. Earnings per share was $-65.18.
| Revenue | 8.57M |
| Gross Profit | -313.00K |
| Operating Income | -276.01M |
| Net Income | -276.13M |
| EBITDA | -266.00M |
| EBIT | -276.01M |
| Earnings Per Share (EPS) | -65.18 |
Balance Sheet
The company has $25.84M in cash and $57.87M in debt, giving a net cash position of -$32.03M.
| Cash & Cash Equivalents | 25.84M |
| Total Debt | 57.87M |
| Net Cash | -32.03M |
| Retained Earnings | -1.97B |
| Total Assets | 142.71M |
| Working Capital | -64.12M |
Cash Flow
In the last 12 months, operating cash flow was -$192.98M and capital expenditures -$1.22M, giving a free cash flow of -$194.20M.
| Operating Cash Flow | -192.98M |
| Capital Expenditures | -1.22M |
| Free Cash Flow | -194.20M |
| FCF Per Share | -45.84 |
Margins
Gross margin is -3.65%, with operating and profit margins of -3.22K% and -3.22K%.
| Gross Margin | -3.65% |
| Operating Margin | -3.22K% |
| Pretax Margin | -3.22K% |
| Profit Margin | -3.22K% |
| EBITDA Margin | -3.10K% |
| EBIT Margin | -3.22K% |
| FCF Margin | -2.27K% |
Dividends & Yields
ATRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -629.15% |
| FCF Yield | -325.45% |
Analyst Forecast
The average price target for ATRA is $18, which is 73.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $18 |
| Price Target Difference | 73.7% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Jun 20, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Jun 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -22.67 |
| Piotroski F-Score | 3 |